Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.35 |
| ▸ | EBP | Q15125 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 3/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19055353 | 1.00 | SIGMAR1 (0.35) | SIGMAR1EBPFDPSGNAI3GNAO1 | |
| SCHEMBL26003657 | 0.96 | SIGMAR1 (0.33) | SIGMAR1EBPFDPSGNAI3GNAO1 | |
| SCHEMBL23733442 | 0.91 | MEN1 (0.36) | SIGMAR1EBPFDPSGNAI3GNAO1 | |
| SCHEMBL23733448 | 0.91 | MEN1 (0.36) | SIGMAR1EBPFDPSGNAI3GNAO1 | |
| SCHEMBL20781702 | 0.91 | MEN1 (0.36) | SIGMAR1EBPFDPSGNAI3GNAO1 | |
| SCHEMBL21613903 | 0.89 | MAPT (0.33) | SIGMAR1MEN1POLBMAPTKMT2A | |
| SCHEMBL23733462 | 0.85 | GNAI3 (0.38) | FDPSGNAI3GNAO1GNAI1MAPT | |
| SCHEMBL8262509 | 0.84 | PHGDH (0.34) | SIGMAR1MEN1MAPTKMT2A | |
| SCHEMBL24599674 | 0.83 | FDPS (0.41) | FDPSMAPTLMNA | |
| SCHEMBL14238528 | 0.83 | FDPS (0.41) | FDPSMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037573-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037573-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | SIGMAR1 3645/4885EBP 1465/4885FDPS 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.